Journal of Pharmacy Practice and Pharmaceutical Sciences

ISSN: 2652-2536

Editorial

Lithium as a Dietary Supplement

Antoine Al-Achi*

College of Pharmacy and Health Sciences, Campbell University, USA

Received: 13 August 2019

Accepted: 22 August 2019

Version of Record Online: 06 September 2019

Citation:

Al-Achi A (2019)Lithium as a Dietary Supplement. J Pharm Pract Pharm Sci 2019(1): 75-76.

Correspondence should be addressed to
Antoine Al-Achi, USA

E-mail: alachi@campbell.edu
DOI: 
10.33513/PPPS/1901-16

Copyright:

Copyright © 2019 Antoine Al-Achi. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and work is properly cited.

Mental disorders account for 40% of causes of disabilities in the developing world as well as in the United States[1]. It is also estimated that approximately 25% of adult Americans suffer from some form of mental illness, including major depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder [1]. These disorders may be treated with antidepressant medications or lithium. Although the use of lithium is on the decline to treat mood disorders [2], lithium remains to be a successful treatment of affective disorders (unipolar, bipolar, and schizoaffective illness) in young and older patient populations alike [3,4]. It often produces positive results and augments antidepressant-resistant unipolar major depressive disorder [5,6]. It is estimated that about 80% of patients with mania (i.e., bipolar) respond to lithium therapy in the acute phase [4]. Affective disorders are commonly associated with severe morbidity and mortality-related suicide [4,7]. Lithium therapy has been shown to reduce the risk of suicide in patients with mood disorders, in particular, those with unipolar and bipolar mood disorder patients [5,8]. A 12-hour plasma lithium concentration of 0.5-0.7 mmol/L has been established to be the most effective [8]. This therapeutic range may be established by a daily lithium dose of 900 mg [6]. Although this therapeutic range of lithium does not produce significant side effects [3,8], it is considered to be narrow, and thus, it is subject to result in some form of toxicity (75% of patients on long-term lithium therapy will experience some toxic effect) [8]. Lithium neurotoxicity can occur within the therapeutic levels, which may include neuroleptic malignant syndrome (altered mental status, autonomic dysregulation, fever, and muscular stiffness) [8]. Elderly patients may be more susceptible to the neurotoxicity, and thus, they should be given a lower lithium dose to avoid it [9]. Much of the toxicity of lithium may be attributed to drug overdose, dehydration, and pharmacokinetic interactions with other drugs (angiotensin receptor blockers, non-steroidal anti-inflammatory drugs, and diuretics) [8]. Lithium renal clearance can be reduced with age, and therefore, the dose of lithium should be lowered with advancing age in order to avoid toxicity [10]. Based on a Safety Data Sheet (SDS) available on the Internet [https://www.nwmissouri.edu/naturalsciences/sds/l/Lithium%20carbonate.pdf], lithium is available as lithium carbonate salt with a solubility in water of 8.4 g/L at 20 °C. A 1 g/L solution in water produces a pH of 9.0-11.0 at room temperature. Lithium carbonate is the most common form of lithium salts available for therapy. Lithium side effects following a high dose include a dulled personality, memory loss, reduced emotions, tremors, and weight gain [1]. It is interesting to note that 80% of bipolar patients have some vitamin B deficiencies [1]. Although the role of side effects remains unclear with lithium therapy adherence, it is estimated that over 40% of patients who are on lithium therapy are classified as non-adherent [2]. Lithium is available on the market as capsules, solutions, immediate-release, and extended-release tablets. A new pharmaceutical innovation on delivering lithium carbonate was proposed by which six tablets of lithium (one immediate-release and the others extended-release) were placed inside a capsule. This dosage form was reported to provide a 24-hour extended-release delivery for lithium [11]. Lithium was reported to prevent or reduce neuropathic pain associated with the treatment of the chemotherapeutic agent Taxol[12].

Dietary supplements of lithium are available on the market. These include products-containing lithium in the form of a liquid ionic form (500 mcg/10 drops), tablets (10 mg of lithium orotate), and capsules (lithium orotate 5 mg; lithium aspartate 5-10 mg), among others. Although the dose of lithium in these supplements is much lower than that found in pharmaceuticals, overdosing with the supplements can produce mild tremor with severe nausea and vomiting that may require emergency medical attention [13]. Also, supplementing with dietary lithium products can cause drug/supplement interactions, and therefore, it must be communicated to health care providers. For instance, lithium interacts with the antibiotic metronidazole, and replacement antibiotic must be given instead when needed [14]. The use of dietary lithium products by the public is commonly cited for its potential known positive effects on depression and suicide prevention [15]. Moreover, lithium is believed to enhance cognitive ability and to reduce the incidence of dementia [15]. Long-term treatment with lithium in older adults who had amnestic mild cognitive impairment showed a definite improvement in cognitive functions as well as modifications of cerebrospinal fluid biomarkers associated with Alzheimer’s disease [16]. However, it should be noted that a significant lowering in kidney concentrating ability may be encountered in the long-term lithium-treated patients [17]. In the form of lithium orotate, lithium is readily available in its ionic form following its dissolution in water. According to an SDS [http://materie-prime.farmalabor.it/sds/01412_en.pdf] for lithium orotate, the salt is white crystalline powder with a neutral odor having a flashpoint greater than 300 °C. The salt is slightly soluble in water at room temperature. Incidentally, the orotate ion can cross the blood-brain barrier more readily and quickly than the carbonate ion, and thus administering lithium as orotate is a better and more efficient way for therapy [1]. The orotate form also allows a lower dose of lithium while reducing the possibility of side effects development [1].

In conclusion, the dietary supplement form of lithium (lithium orotate) appears to have some beneficial effects for maintaining a healthy mood provided the patient coordinates their use of this supplement with a primary health care provider.

References

  1. Lakhan SE, Vieira KF (2008) Nutritional therapies for mental disorders. Nutr J 7: 2.
  2. Gitlin M (2016) Lithium side effects and toxicity: Prevalence and management strategies. J Bipolar Disord 24: 27.
  3. CoppenA, Abou-Saleh MT (1988) Lithium therapy: From clinical trials to practical management. ActaPsychiatrScand 78: 754-762.
  4. Lepkifker E, Iancu I, Horesh N, Strous RD, Kotler M (2007) Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation. Depress Anxiety 24: 571-576.
  5. Rihmer Z, Gonda X (2011) Antidepressant-Resistant depression and antidepressant-associated suicidal behaviour: The role of underlying bipolarity. Depression Research and Treatment.
  6. Alevizos B, Alevizos E, Leonardou A, Zervas I (2012) Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study. Psychiatriki 23: 143-148.
  7. Edokpolo O, Fyyaz M (2012) Lithium toxicity and neurologic effects: Probable neuroleptic malignant syndrome resulting from lithium toxicity. Case Reports in Psychiatry.
  8. Coppen A (2000) Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry 61: 52-56.
  9. Arnaoudova MD (2014) Lithiumtoxicityin elderly-A case report and discussion. Journal of IMAB 20: 519-522.
  10. Norman TR, Walker RG, Burrows GD (1984) Renal function related changes in lithiumkinetics.ClinPharmacokinet 9: 349-353.
  11. Pietkiewicz P, Sznitowska M, Dorosz A, Lukasiak J (2003) Lithium carbonate 24-hour extended-release capsule filled with 6 mm tablets.BollChim Farm 142: 69-71.
  12. Gao M, Yan X, H-RWeng (2013) Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain. Neuroscience 254: 301-311.
  13. Pauzé DK, Brooks DE (2007) Lithium toxicity from an internet dietary supplement. J Med Toxicol 3: 61-62.
  14. VanWeringh G, Uitvlugt EB, Ponjee GHM, M Jalink G (2017) Confusion caused by dietary supplement lithium orotate. TijdschriftVoorPsychiatrie 59: 234-237.
  15. Post RM (2018) The new news about lithium: An underutilized treatment in the United States. Neuropsychopharmacology 43: 1174-1179.
  16. Forlenza OV, Radanovic M, TalibLL, Gattaz WF (2019) Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial Br J Psychiatry 5: 1-7.
  17. Dastych M, Synek O, Gottwaldová J (2019) Impact of long-term Lithium treatment on renal function in patients with bipolar disorder based on novel biomarkers. J Clin Psychopharmacol 39: 238-242.
Ocimum Scientific Publishers

This work is licensed under a Creative Commons Attribution 4.0 International License.  Creative Commons License

Copyright © 2019 - All Rights Reserved - ocimumpublishers.com